188 related articles for article (PubMed ID: 23570180)
1. SOP 04: Data collection forms (case report forms).
Onkologie; 2003 Oct; 26 Suppl 6():15-22. PubMed ID: 23570180
[No Abstract] [Full Text] [Related]
2. SOP 08: Reporting of adverse events.
Onkologie; 2003 Oct; 26 Suppl 6():41-2. PubMed ID: 23570185
[No Abstract] [Full Text] [Related]
3. SOP 07: Data flow, monitoring, and archiving.
Onkologie; 2003 Oct; 26 Suppl 6():36-7. PubMed ID: 23570183
[No Abstract] [Full Text] [Related]
4. SOP 07a: Monitoring of a trial under CESAR responsibility.
Onkologie; 2003 Oct; 26 Suppl 6():38-40. PubMed ID: 23570184
[No Abstract] [Full Text] [Related]
5. SOP 06: Selecting the participating centers and activation of a trial.
Onkologie; 2003 Oct; 26 Suppl 6():34-5. PubMed ID: 23570182
[No Abstract] [Full Text] [Related]
6. SOP 09: Statistical design and analysis.
Onkologie; 2003 Oct; 26 Suppl 6():43-7. PubMed ID: 23570186
[No Abstract] [Full Text] [Related]
7. SOP 14: Population pharmacokinetic analysis.
Onkologie; 2003 Oct; 26 Suppl 6():60-6. PubMed ID: 23570191
[No Abstract] [Full Text] [Related]
8. SOP 10: Study report and publication.
Onkologie; 2003 Oct; 26 Suppl 6():48-9. PubMed ID: 23570187
[No Abstract] [Full Text] [Related]
9. SOP 05: Patient information and informed consent.
Onkologie; 2003 Oct; 26 Suppl 6():23-33. PubMed ID: 23570181
[No Abstract] [Full Text] [Related]
10. SOP 13: Pharmacokinetic data analysis.
Onkologie; 2003 Oct; 26 Suppl 6():56-9. PubMed ID: 23570190
[No Abstract] [Full Text] [Related]
11. SOP 03: Preparation and structure of trial protocols.
Onkologie; 2003 Oct; 26 Suppl 6():11-4. PubMed ID: 23570179
[No Abstract] [Full Text] [Related]
12. SOP 12: Validation of bioanalytical methods.
Onkologie; 2003 Oct; 26 Suppl 6():52-5. PubMed ID: 23570189
[No Abstract] [Full Text] [Related]
13. SOP 11: Quality assurance.
Onkologie; 2003 Oct; 26 Suppl 6():50-1. PubMed ID: 23570188
[No Abstract] [Full Text] [Related]
14. [Hospital network in pediatric oncology].
Doz F
Arch Pediatr; 2006 Jun; 13(6):635-7. PubMed ID: 16697587
[No Abstract] [Full Text] [Related]
15. SOP 01: Clinical investigations in CESAR.
Onkologie; 2003 Oct; 26 Suppl 6():1-4. PubMed ID: 23570177
[No Abstract] [Full Text] [Related]
16. SOP 02: Evaluation and selection of a clinical trial proposal for CESAR.
Onkologie; 2003 Oct; 26 Suppl 6():5-10. PubMed ID: 23570178
[No Abstract] [Full Text] [Related]
17. [Recording and reporting adverse reactions in clinical trials. New legal provisions according to the 12th Law Amending the German Drug Law (AMG) and the Ordinance on GCP (GCP-V)].
Eckhardt K; Cremer-Schaeffer P; König J; Paeschke N
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):173-80. PubMed ID: 15726458
[TBL] [Abstract][Full Text] [Related]
18. Rapid reporting and review of an increased incidence of a known adverse event.
Sargent DJ; Goldberg RM; Mahoney MR; Hillman DW; McKeough T; Hamilton SF; Darcy JM; Anderson VL; Krook JE; O'Connell MJ
J Natl Cancer Inst; 2000 Jun; 92(12):1011-3. PubMed ID: 10861314
[No Abstract] [Full Text] [Related]
19. Cancer drugs. Weighing the risks and benefits.
Bren L
FDA Consum; 2007; 41(1):10-9. PubMed ID: 17342832
[TBL] [Abstract][Full Text] [Related]
20. An audience with Tatiana Prowell. Interviewed by Asher Mullard.
Prowell T
Nat Rev Drug Discov; 2014 Jun; 13(6):410-1. PubMed ID: 24875091
[No Abstract] [Full Text] [Related]
[Next] [New Search]
